[HTML] sciencedirect.com

[HTML][HTML] Real-world insights into evolocumab use in patients with hyperlipidemia: Canadian analysis from the ZERBINI study

M Gupta, GBJ Mancini, RJ Wani, V Ahooja, J Bergeron… - CJC open, 2022 - Elsevier
Abstract Background The 2021 Canadian Cardiovascular Society guidelines recommend
proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with …
被引用次数：21 相关文章
[HTML] cjcopen.ca

[HTML][HTML] Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study

M Gupta, GBJ Mancini, RJ Wani, V Ahooja, J Bergeron… - CJC Open, 2022 - cjcopen.ca
Abstract Background The 2021 Canadian Cardiovascular Society guidelines recommend
proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with …

Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study.

M Gupta, GBJ Mancini, RJ Wani, V Ahooja, J Bergeron… - CJC Open, 2022 - europepmc.org
Background The 2021 Canadian Cardiovascular Society guidelines recommend proprotein
convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with atherosclerotic …
[HTML] nih.gov

[HTML][HTML] Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study

M Gupta, GBJ Mancini, RJ Wani, V Ahooja, J Bergeron… - CJC Open, 2022 - ncbi.nlm.nih.gov
Background The 2021 Canadian Cardiovascular Society guidelines recommend proprotein
convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with atherosclerotic …

Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study

M Gupta, GBJ Mancini, RJ Wani, V Ahooja… - CJC …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The 2021 Canadian Cardiovascular Society guidelines recommend proprotein
convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with atherosclerotic …